Last updated: 2026-09-09 04:51:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Rapport Therapeutics, Inc. (RAPP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $46.06, with a market capitalization of $2.20B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.06 to $52.93. This page covers its latest market performance, valuation, price trends and company information.
$2.20B | |
$45.01 | |
$52.93 | |
$6.43 | |
$45.77 | |
422.18K | |
355.56K | |
-- | |
$52.93 | |
$22.06 | |
-- | |
-- |
Rapport Therapeutics, Inc. (RAPP) last closed at $45.77 as of 2026-09-08 23:31:00, unchanged from the previous close of $45.77.
During the latest regular trading session, RAPP traded between $6.43 and $52.93, with a volume of 422.18K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Rapport Therapeutics, Inc. (RAPP) moved from $50.83 to $46.06, representing a decline of 9.38% ($4.77).
The stock traded between $43.73 and $52.93 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 276.68 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 77.7%
RAPP is currently trading at $46.06, placing it 77.7% of the way from its 52-week low of $22.06 to its 52-week high of $52.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 84 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rapport Therapeutics, Inc. (RAPP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.